Case 1: Newly Diagnosed CLL/SLL without del(17p)/TP53 mutation in a patient <65 years without significant comorbidities
Before completing this activity, we recommended viewing Guideline Updates and Real-World Experiences in CLL: State-of-the-Art Evidence and Next Questions.
Earn CME/CE while testing your knowledge. Try your skills at this challenging case in CLL/SLL.
This program is intended for physicians, physician assistants, nurses, pharmacists, and other healthcare providers who care for patients with CLL/SLL.
Upon completion of this activity, participants should be able to:
- Identify clinical challenges in managing patients with CLL/SLL.
- Develop an evidence-based approach for the management of these patients.
Jeremy S. Abramson, MD, MMSc
Department of Medicine
Harvard Medical School
Director, Center for Lymphoma
Massachusetts General Hospital
NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest. In addition, all faculty presentations have been reviewed to ensure education is fair and balanced and that clinical content presented supports safe, effective patient care. Individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter.
NCCN continuing education considers financial relationships to create a conflict of interest when an individual has both a financial relationship with a commercial interest and the opportunity to affect continuing education content about the products or services of a commercial interest with which he/she has a financial relationship.
NCCN continuing education considers relevant financial relationships as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.
The faculty listed below discloses the following relevant financial relationships:
Jeremy S. Abramson, MD, MMSc, has disclosed that he has received consulting fees from AstraZeneca, BeiGene, Bluebird Bio, Celgene/Bristol-Myers Squibb, Epizyme, Genentech, Genmab, Incyte, Kite, and Kymera.
The activity planning staff listed below discloses no relevant financial relationships:
CCO: Bing-E Xu, PhD; Timothy A. Quill, PhD; Megan Cartwright, PhD; Jason J. Everly, PharmD, BCOP, CHCP; Kevin Obholz, PhD; June Wasserstrom; Jim Mortimer
NCCN: Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Karen Kanefield; Kathy Ann Smith, CHCP
The NCCN clinical staff listed below discloses no relevant financial relationships:
Hema Sundar, PhD
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NCCN designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NCCN designates this educational activity for a maximum of 0.25 contact hour.
NCCN designates this knowledge-based continuing education activity for 0.25 contact hours (0.025 CEUs) of continuing education credit. UAN: JA4008196-0000-21-103-H01-P
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until July 22, 2022. PAs should only claim credit commensurate with the extent of their participation.
- 0.25 AAPA Category 1 CME credit
- 0.25 ACPE contact hours
- 0.25 AMA PRA Category 1 Credit™
- 0.25 ANCC contact hours
- 0.25 Participation